checkAd

Tauriga Sciences Inc. Acquires Equity Stake in Israeli Biotechnology Firm that Develops Drugs Based on Cannabinoid Molecules

Nachrichtenquelle: globenewswire
01.03.2021, 16:56  |  126   |   |   

NEW YORK, NY, March 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has acquired an equity stake in an Israeli biotechnology firm that develops drugs based on Cannabinoid molecules. The Company believes that this equity stake is potentially complementary to its own ongoing Pharmaceutical development efforts (also involving Cannabinoid molecules).        

The Company plans to File a Form 8-K, within the next several days, to disclose the details of this above-referenced equity stake.  

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives.  The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment.  The main product line, branded as Tauri-Gum, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum Flavors: Peach-Lemon, Black Currant) & (Vitamin C + Zinc “Immune Booster” Flavor: Pear Bellini).  The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com

Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative.  This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum.  The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”.  On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.

Seite 1 von 2
Zink jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de



Diesen Artikel teilen
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Tauriga Sciences Inc. Acquires Equity Stake in Israeli Biotechnology Firm that Develops Drugs Based on Cannabinoid Molecules NEW YORK, NY, March 01, 2021 (GLOBE NEWSWIRE) - via NewMediaWire - Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel